According to a new report North America Pharmacogenomics Market, published by KBV research, the North America Pharmacogenomics Market would witness market growth of 8.1% CAGR during the forecast period (2019-2025).
The Hospitals and Clinics market dominated the Canada Pharmacogenomics Market by End User in 2018, growing at a CAGR of 8.2 % during the forecast period. The Research Institutions market is expected to witness highest CAGR of 8.8% during (2019 - 2025).
The USA market dominated the North America Mass Spectrometry Market by Country in 2018, growing at a CAGR of 8.6 % during the forecast period. The Canada market is expected to witness a CAGR of 9.4% during (2019 - 2025). Additionally, The Mexico market is expected to witness a CAGR of 11.5% during (2019 - 2025).
The Oncology market dominated the North America Pharmacogenomics Market by Application in 2018; thereby, achieving a market value of $1,560.9 million by 2025, growing at a CAGR of 7.5 % during the forecast period. The Psychiatry market is expected to witness a CAGR of 8.6% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/north-america-pharmacogenomics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
By Technology
By Application
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
